PATENT CLAIM ANALYSIS

Application Number: 15777078
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["514", "370000"]

Abstract:
Disclosed is a method utilizing (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or an analogue, pharmaceutically acceptable salt or solvate thereof for the treatment of a retinal disease, more specifically using mirabegron for the treatment of age-related macular degeneration. Also Disclosed is a pharmaceutical composition, a medicament and a kit for the treatment of age-related macular degeneration.

Claim (Index 22):
The method according to  claim 16 , wherein the (R)-2-(2-aminothiazol-4-yl)-4\u2032-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or an analogue or a pharmaceutically acceptable salt or solvate thereof is administered to the subject in need thereof orally or topically.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 93.0
- Lexical Diversity: 1.55102
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13073677', '13748956', '10534290', '11057009', '13248840']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.776244707044231
- 35 USC 102 Novelty (BERT): 0.4868873148644445
- Combined Prediction Score: 0.7473089678262523
- Mean Citation Score: 216.28647800000005
- Max Citation Score: 228.91573
- Similarity Product: 184.7249066112053

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test